Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05500807 · ClinicalTrials.gov registry record · Phase 1
Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
A Phase 1 study of Von Willebrand Disease, Type 3 and Concomitant VWD and Hemophilia, sponsored by Bleeding and Clotting Disorders Institute Peoria, Illinois.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 9
- Study locations
NCT05500807: Recruiting Phase 1 study of Von Willebrand Disease, Type 3 and Concomitant VWD and Hemophilia, sponsored by Bleeding and Clotting Disorders Institute Peoria, Illinois.
NCT05500807 is a Phase 1 study of Von Willebrand Disease, Type 3 and Concomitant VWD and Hemophilia that is actively recruiting participants, run by Bleeding and Clotting Disorders Institute Peoria, Illinois. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05500807, a Phase 1 study of Von Willebrand Disease, Type 3 and Concomitant VWD and Hemophilia, is actively recruiting participants, sponsored by Bleeding and Clotting Disorders Institute Peoria, Illinois.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 9
- Study locations
Study Summary
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. Severe bleeding events require VWF concentrates administered solely through intravenous access. Emicizumab (Hemlibra) is a monoclonal bispecific antibody developed to bind activated FIX and FX and mimic FVIII cofactor functionality. Hemlibra is administered via subcutaneous injection rather than intravenous infusion. The hypothesis of this study is that Emicizumab is safe and efficacious for prophylaxis in severe VWD and concomitant VWD/hemophilia patients.
Primary Outcome
Establish bleed occurrence during treatment evaluated through descriptive statistical analysis to determine proof of principle
Conditions Studied
Interventions
- DRUG Emicizumab
Study Locations (9)
California
- The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD) - Orange
- Stanford University: Stanford Children's Health - Redwood City
Florida
- University of Miami - Miller School of Medicine - Coral Gables
- St. Joseph's Children's Hospital - Center for Bleeding and Clotting Disorders - Tampa
Michigan
- University of Michigan Medical School - Ann Arbor
- Central Michigan University: Children's Hospital of Michigan - Mount Pleasant
Illinois
- Bleeding and Clotting Disorders Institute (BCDI) - Peoria
Indiana
- Innovative Hematology, Inc. (IHI) - Indianapolis
Washington
- Washington Center for Bleeding Disorders - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT05500807 shows while recruiting
NCT05500807 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 2 conditions, with Von Willebrand Disease, Type 3 appearing as the primary indexed condition, and to 1 intervention - of which Emicizumab is the first listed.
NCT05500807 lists 9 locations in 6 states (California, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT05500807 about?
NCT05500807 is a clinical study titled "Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A". Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. Severe bleeding events require VWF concentrates administered solely through i...
What is the current status of trial NCT05500807?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-11-01. Estimated completion is 2027-06.
What conditions does trial NCT05500807 study?
This clinical trial studies the following conditions: Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia.
What interventions are being tested in trial NCT05500807?
The interventions under investigation include: Emicizumab (DRUG).
Who is sponsoring clinical trial NCT05500807?
This trial is sponsored by Bleeding and Clotting Disorders Institute Peoria, Illinois, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05500807 being conducted?
This trial has 9 study locations across California, Florida, Illinois, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Von Willebrand Disease, Type 3
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05500807's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI